BeOne Medicines AG Reports Significant Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 01 2026
0mins
Should l Buy ONC?
Source: Yahoo Finance
BeOne Medicines AG's stock rose by 6.01% and reached a 20-day high, reflecting positive investor sentiment amid broader market gains, with the Nasdaq-100 up 0.65% and the S&P 500 up 0.49%.
The surge is attributed to the company's announcement regarding the ZIIHERA trial results, which demonstrated significant improvements in overall survival for patients with HER2+ gastroesophageal adenocarcinoma. The trial showed a median overall survival of 26.4 months, marking a 28% reduction in the risk of death compared to the control group, thus highlighting the potential of ZIIHERA in treatment.
These promising results not only enhance BeOne's position in the oncology market but also suggest a potential expansion of treatment access in the Asia-Pacific region, addressing a critical need for effective therapies. Investors are likely to remain optimistic as the company moves forward with its plans.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 284.080
Low
385.00
Averages
403.76
High
424.00
Current: 284.080
Low
385.00
Averages
403.76
High
424.00
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BeOne Medicine's BGB-B2033 Receives FDA Orphan Drug Designation
- Orphan Drug Status: BeOne Medicine's BGB-B2033 has received orphan drug designation from the FDA for hepatocellular carcinoma, the most common type of liver cancer, marking a significant advancement in the company's oncology portfolio.
- Anti-Tumor Activity: BGB-B2033 is an IgG-based bispecific antibody currently in phase 1 trials targeting GPC3 and 4-1BB, demonstrating potential anti-tumor activity that could provide new treatment options for liver cancer patients.
- Combination Therapy Potential: BeOne indicates that the anti-tumor activity of BGB-B2033 may be enhanced when used in conjunction with Tevimbra (tislelizumab), an IgG4 anti-PD-1 monoclonal antibody, which could improve treatment outcomes.
- Market Outlook: With the orphan drug designation, BeOne Medicine's competitiveness in the liver cancer treatment market is strengthened, likely attracting increased investor interest in its future clinical developments and market potential.
See More
BeOne Medicines AG Raises 2026 Revenue Guidance Amid Strong Q4 Results
- Significant Revenue Growth: BeOne Medicines AG reported global revenues of $1.5 billion for Q4 2025, reflecting a 33% increase from the previous quarter, while projecting $5.3 billion for 2026, a 40% year-over-year growth, indicating strong market performance and growth potential.
- Strong Brukinsa Performance: The company's lymphoma and leukemia treatment, Brukinsa, generated revenues of $1.1 billion and $3.9 billion for Q4 and the full year, respectively, marking increases of 38% and 49% from prior periods, further solidifying its market position in oncology.
- Analyst Price Target Increase: On February 27, Truist Securities raised its price target for BeOne Medicines AG from $400 to $412 while maintaining a Buy rating, reflecting confidence in the company's future growth, especially following the release of its fiscal 2026 revenue guidance.
- Market Expectation Pressure: Although the fiscal 2026 revenue guidance ranges from $6.2 billion to $6.4 billion, closely aligning with consensus estimates of $6.4 billion, analysts noted that this expectation has added pressure on the stock price, indicating a cautious market outlook on the company's future growth.
See More
BeiGene to Announce Q4 Earnings on February 26
- Earnings Announcement: BeiGene is set to release its Q4 2023 earnings report on February 26 before the market opens, with investors keenly awaiting performance insights to gauge future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $1.30, with revenue projected at $1.45 billion, reflecting a robust year-over-year growth of 31.8%, indicating strong momentum in the biopharmaceutical sector.
- Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions but five downward adjustments, while revenue estimates experienced one upward revision and two downward adjustments, suggesting a cautious market outlook on the company's performance.
- Industry Context: The earnings release will coincide with BeOne Medicines AG's presentation at the 44th Annual J.P. Morgan Healthcare Conference, potentially influencing investor sentiment towards the broader biopharmaceutical industry.
See More
Three Stocks Set to Outperform the Market in 2026
- Alphabet Cloud Growth: Alphabet's cloud business had an annual revenue run rate of approximately $70 billion at the end of 2025, with a backlog growth exceeding 100% year-over-year to $240 billion in Q4, which is expected to significantly enhance the company's profitability in 2026 and solidify its leadership in the AI sector.
- BeOne Drug Development Progress: BeOne Medicines plans to announce Phase 3 study results for Brukinsa in combination with rituximab in the first half of 2026, and is expected to gain U.S. regulatory approval for sonrotoclax, further enhancing its competitiveness in the blood cancer treatment market.
- Rhythm Drug Approval Outlook: Rhythm Pharmaceuticals' Imcivree is anticipated to receive FDA approval for treating acquired hypothalamic obesity by March 20, 2026, which would significantly expand its market potential as this condition affects more patients than the combined total of its three existing indications.
- Multiple Clinical Trial Data Releases: Rhythm also plans to report top-line data from a Phase 3 study evaluating Imcivree in four other genetic diseases in Q1 2026 and disclose results from an exploratory Phase 2 study on Prader-Willi syndrome in the first half of the year, further boosting investor confidence.
See More
Amazon and BeOne Medicines Show Promising Prospects
- Amazon Earnings Growth: Amazon is expected to report robust earnings growth in its upcoming Q4 2025 results, driven by efficiency improvements, despite lagging behind the S&P 500 over the past 12 months.
- BeOne Drug Approvals: BeOne Medicines' flagship drug, Brukinsa, has become the gold standard for treating various blood cancers, and the recent Chinese regulatory approval for sonrotoclax is expected to boost sales in both the U.S. and Europe.
- Enterprise Products Partners Appeal: With a forward distribution yield of 6.6% and 27 consecutive years of dividend increases, Enterprise Products Partners is attractive for income investors, and the anticipated growth in natural gas demand from AI data center construction could enhance its market position.
- Investor Attention: Although Amazon was not included in the Motley Fool Stock Advisor's top investment picks, its AWS division is projected to benefit significantly from the widespread adoption of AI agents in 2026, potentially enhancing the company's competitive edge.
See More
February Investment Opportunities: Amazon and Three Stocks to Buy
- Amazon Earnings Growth: Amazon (AMZN) has lagged behind the S&P 500 over the past 12 months, but its fourth-quarter 2025 earnings are expected to show robust growth, potentially driving stock price recovery with a market cap of $2.6 trillion and a gross margin of 50.05%.
- BeOne Drug Approval: BeOne Medicines (ONC) has seen its stock soar over 50% in the past year, with its flagship product Brukinsa now the gold standard for blood cancer treatment, and sales are expected to continue rising in both the U.S. and Europe, giving it a market cap of $38 billion.
- New Drug Application Progress: BeOne recently received Chinese regulatory approval for sonrotoclax to treat relapsed/refractory (R/R) lymphoma and is poised to file for accelerated approval of BGB-16673 pending positive Phase 2 clinical results, which could further enhance its growth trajectory.
- Enterprise Products Partners Dividends: Enterprise Products Partners (EPD) offers a forward distribution yield of 6.6%, having increased its dividends for 27 consecutive years, and the anticipated boom in AI data center construction is expected to drive natural gas demand growth, enhancing its market performance.
See More
BeOne Medicine's BGB-B2033 Receives FDA Orphan Drug Designation
- Orphan Drug Status: BeOne Medicine's BGB-B2033 has received orphan drug designation from the FDA for hepatocellular carcinoma, the most common type of liver cancer, marking a significant advancement in the company's oncology portfolio.
- Anti-Tumor Activity: BGB-B2033 is an IgG-based bispecific antibody currently in phase 1 trials targeting GPC3 and 4-1BB, demonstrating potential anti-tumor activity that could provide new treatment options for liver cancer patients.
- Combination Therapy Potential: BeOne indicates that the anti-tumor activity of BGB-B2033 may be enhanced when used in conjunction with Tevimbra (tislelizumab), an IgG4 anti-PD-1 monoclonal antibody, which could improve treatment outcomes.
- Market Outlook: With the orphan drug designation, BeOne Medicine's competitiveness in the liver cancer treatment market is strengthened, likely attracting increased investor interest in its future clinical developments and market potential.
See More
BeOne Medicines AG Raises 2026 Revenue Guidance Amid Strong Q4 Results
- Significant Revenue Growth: BeOne Medicines AG reported global revenues of $1.5 billion for Q4 2025, reflecting a 33% increase from the previous quarter, while projecting $5.3 billion for 2026, a 40% year-over-year growth, indicating strong market performance and growth potential.
- Strong Brukinsa Performance: The company's lymphoma and leukemia treatment, Brukinsa, generated revenues of $1.1 billion and $3.9 billion for Q4 and the full year, respectively, marking increases of 38% and 49% from prior periods, further solidifying its market position in oncology.
- Analyst Price Target Increase: On February 27, Truist Securities raised its price target for BeOne Medicines AG from $400 to $412 while maintaining a Buy rating, reflecting confidence in the company's future growth, especially following the release of its fiscal 2026 revenue guidance.
- Market Expectation Pressure: Although the fiscal 2026 revenue guidance ranges from $6.2 billion to $6.4 billion, closely aligning with consensus estimates of $6.4 billion, analysts noted that this expectation has added pressure on the stock price, indicating a cautious market outlook on the company's future growth.
See More
BeiGene to Announce Q4 Earnings on February 26
- Earnings Announcement: BeiGene is set to release its Q4 2023 earnings report on February 26 before the market opens, with investors keenly awaiting performance insights to gauge future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $1.30, with revenue projected at $1.45 billion, reflecting a robust year-over-year growth of 31.8%, indicating strong momentum in the biopharmaceutical sector.
- Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions but five downward adjustments, while revenue estimates experienced one upward revision and two downward adjustments, suggesting a cautious market outlook on the company's performance.
- Industry Context: The earnings release will coincide with BeOne Medicines AG's presentation at the 44th Annual J.P. Morgan Healthcare Conference, potentially influencing investor sentiment towards the broader biopharmaceutical industry.
See More
Three Stocks Set to Outperform the Market in 2026
- Alphabet Cloud Growth: Alphabet's cloud business had an annual revenue run rate of approximately $70 billion at the end of 2025, with a backlog growth exceeding 100% year-over-year to $240 billion in Q4, which is expected to significantly enhance the company's profitability in 2026 and solidify its leadership in the AI sector.
- BeOne Drug Development Progress: BeOne Medicines plans to announce Phase 3 study results for Brukinsa in combination with rituximab in the first half of 2026, and is expected to gain U.S. regulatory approval for sonrotoclax, further enhancing its competitiveness in the blood cancer treatment market.
- Rhythm Drug Approval Outlook: Rhythm Pharmaceuticals' Imcivree is anticipated to receive FDA approval for treating acquired hypothalamic obesity by March 20, 2026, which would significantly expand its market potential as this condition affects more patients than the combined total of its three existing indications.
- Multiple Clinical Trial Data Releases: Rhythm also plans to report top-line data from a Phase 3 study evaluating Imcivree in four other genetic diseases in Q1 2026 and disclose results from an exploratory Phase 2 study on Prader-Willi syndrome in the first half of the year, further boosting investor confidence.
See More
Amazon and BeOne Medicines Show Promising Prospects
- Amazon Earnings Growth: Amazon is expected to report robust earnings growth in its upcoming Q4 2025 results, driven by efficiency improvements, despite lagging behind the S&P 500 over the past 12 months.
- BeOne Drug Approvals: BeOne Medicines' flagship drug, Brukinsa, has become the gold standard for treating various blood cancers, and the recent Chinese regulatory approval for sonrotoclax is expected to boost sales in both the U.S. and Europe.
- Enterprise Products Partners Appeal: With a forward distribution yield of 6.6% and 27 consecutive years of dividend increases, Enterprise Products Partners is attractive for income investors, and the anticipated growth in natural gas demand from AI data center construction could enhance its market position.
- Investor Attention: Although Amazon was not included in the Motley Fool Stock Advisor's top investment picks, its AWS division is projected to benefit significantly from the widespread adoption of AI agents in 2026, potentially enhancing the company's competitive edge.
See More
February Investment Opportunities: Amazon and Three Stocks to Buy
- Amazon Earnings Growth: Amazon (AMZN) has lagged behind the S&P 500 over the past 12 months, but its fourth-quarter 2025 earnings are expected to show robust growth, potentially driving stock price recovery with a market cap of $2.6 trillion and a gross margin of 50.05%.
- BeOne Drug Approval: BeOne Medicines (ONC) has seen its stock soar over 50% in the past year, with its flagship product Brukinsa now the gold standard for blood cancer treatment, and sales are expected to continue rising in both the U.S. and Europe, giving it a market cap of $38 billion.
- New Drug Application Progress: BeOne recently received Chinese regulatory approval for sonrotoclax to treat relapsed/refractory (R/R) lymphoma and is poised to file for accelerated approval of BGB-16673 pending positive Phase 2 clinical results, which could further enhance its growth trajectory.
- Enterprise Products Partners Dividends: Enterprise Products Partners (EPD) offers a forward distribution yield of 6.6%, having increased its dividends for 27 consecutive years, and the anticipated boom in AI data center construction is expected to drive natural gas demand growth, enhancing its market performance.
See More
